Joint efforts urgently needed at times of emerging tuberculosis drug resistance

Clinical Microbiology and Infection

Volumn 23, Issue 3, 2017, Pages 129-130

  Allerberger, F ^a   Cambau, E ^b   Lange, C ^c,d,e,f  

^a AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^b HÔPITAL FERNAND WIDAL   (France)

^c RESEARCH CENTER BORSTEL   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF NAMIBIA   (Namibia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPREOMYCIN; DRUG; ISONIAZID; KANAMYCIN; QUINOLONE DERIVATIVE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; BACTERIAL CLEARANCE; EDITORIAL; EUROPE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE PERSONNEL; HUMAN; MEDICAL EDUCATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; WORK ENVIRONMENT; COMMUNICABLE DISEASE CONTROL; DIAGNOSTIC TEST; DISEASE TRANSMISSION; HEALTH; ORGANIZATION AND MANAGEMENT; PREVENTION AND CONTROL; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

COMMUNICABLE DISEASE CONTROL; DIAGNOSTIC TESTS, ROUTINE; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, BACTERIAL; GLOBAL HEALTH; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84992388176     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.08.023     Document Type: Editorial

References (11)

1. [1] World Health Organization, Global tuberculosis report 2015. World Health Organization Document 2015; WHO/HTM/TB/2015.22, 2015, WHO, Geneva.
2. [2] Chorba, T., Breedlove, B., Depictions of heroism in battle and anguish from tuberculosis. Emerg Inf Dis 22 (2016), 573–574.
3. [3] Tattersall, W.H., The survival of sputum-positive consumptives. A study of 1,192 cases in a county borough between 1914 and 1940. Tubercle 28 (1947), 85–96.
4. [4] Tattersall, W.H., The survival of sputum-positive consumptives. A study of 1,192 cases in a county borough between 1914 and 1940. Part II. Tubercle, 28, 1947 109–14, 123.
5. [5] European Centre for Disease Prevention and Control/WHO Regional Office for Europe, Tuberculosis. Surveillance and monitoring in Europe 2016. 2016, European Centre for Disease Prevention and Control, Stockholm.
6. [6] Fox, G.J., Schaaf, H.S., Mandalakas, A., Chiappini, E., Zumla, A., Marais, B.J., Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases. Clin Microb Infect 23 (2017), 147–153.
7. [7] Hargreaves, S., Lönnroth, K., Nellums, L., Olaru, I., Nathavitharana, R., Norredam, M., et al. Multi-drug resistant tuberculosis in migrants to Europe. Clin Microb Infect 23 (2017), 141–146.
8. [8] Schön, T., Miotto, P., Köser, C., Viveiros, M., Boettger, E., Cambau, E., Mycobacterium tuberculosis drug resistance testing. Clin Microb Infect 23 (2017), 154–160.
9. [9] Walker, T.T., Merker, M., Kohl, T., Crook, D., Derrick, W., Niemann, S., et al. Whole genome sequencing for M/XDR tuberculosis surveillance and for resistance testing. Clin Microb Infect 23 (2017), 161–166.
10. [10] Andre, E., Goeminne, L., Cabibbe, A., Beckert, P., Kabamba Mukadi, B., Mathys, V., et al. Consensus numbering system for the rifampicin resistance-associated rpoB gene of pathogenic mycobacteria. Clin Microb Infect 23 (2017), 167–172.
11. [11] Dheda, K., Chesov, D., Chang, K.C., Lange, C., Clinical management of adults and children with M/XDR-TB. Clin Microb Infect 23 (2017), 131–140.